Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.43 USD
-0.01 (-0.05%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $20.41 -0.02 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 20.43 -0.01(-0.05%)
Will CPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
Other News for CPRX
Dyne stock tumbles 31% amid drug updates, management changes
Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Top 3 Health Care Stocks That May Crash In August
The Latest Analyst Ratings For Catalyst Pharmaceuticals